Skip to content
10-Q

Quarterly Report

Dogwood Therapeutics, Inc. DWTX

0001558370-25-007109

← back to feed
Filed
May 9, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 6, 2025 1.91M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $17.54M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $14.85M
Current Liabilities Q1 2025 · Mar 31, 2025 $2.58M
Current Liabilities Q1 2025 · Dec 31, 2024 $3.18M
Total Liabilities Q1 2025 · Mar 31, 2025 $14.24M
Total Liabilities Q1 2025 · Dec 31, 2024 $30.03M
Current Assets Q1 2025 · Mar 31, 2025 $19.16M
Current Assets Q1 2025 · Dec 31, 2024 $16.54M
Total Assets Q1 2025 · Mar 31, 2025 $96.98M
Total Assets Q1 2025 · Dec 31, 2024 $94.31M
Shares Diluted restated Q1 2025 · Mar 31, 2024 770.32K sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$937.41K
Stockholders Equity Q1 2025 · Mar 31, 2024 $2.65M
Stockholders Equity Q1 2025 · Dec 31, 2023 $3.81M
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$1.68
Eps Basic restated Q1 2025 · Mar 31, 2024 −$1.68
Sga Expense Q1 2025 · Mar 31, 2024 $970.38K
Rd Expense Q1 2025 · Mar 31, 2024 $343.72K
Net Income Q1 2025 · Mar 31, 2024 −$1.29M
Operating Income Q1 2025 · Mar 31, 2024 −$1.31M